T2 Biosystems is a diagnostics & research business based in the US. T2 Biosystems shares (TTOO) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.14 – an increase of 26.32% over the previous week. T2 Biosystems employs 113 staff and has a trailing 12-month revenue of around $7.7 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.14 |
|---|---|
| 52-week range | $0.06 - $6.80 |
| 50-day moving average | $0.12 |
| 200-day moving average | $1.27 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.03 |
Historical closes compared with the close of $0.144 from 2025-05-02
| 1 week (2025-04-25) | 25.22% |
|---|---|
| 1 month (2025-04-04) | 19.01% |
| 3 months (2025-02-05) | -35.14% |
| 6 months (2024-11-05) | -81.93% |
| 1 year (2024-05-03) | -96.13% |
|---|---|
| 2 years (2023-05-04) | -99.50% |
| 3 years (2022-05-04) | 1962.5 |
| 5 years (2020-05-05) | 2978 |
| Revenue TTM | $7.7 million |
|---|---|
| Gross profit TTM | $-19,026,000 |
| Return on assets TTM | -84.85% |
| Return on equity TTM | -622.14% |
| Profit margin | 0% |
| Book value | $-0.62 |
| Market Capitalization | $4.2 million |
TTM: trailing 12 months
We're not expecting T2 Biosystems to pay a dividend over the next 12 months.
T2 Biosystems's shares were split on a 1:100 basis on 12 October 2023 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your T2 Biosystems shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for T2 Biosystems shares which in turn could have impacted T2 Biosystems's share price.
Over the last 12 months, T2 Biosystems's shares have ranged in value from as little as $0.056 up to $6.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while T2 Biosystems's is 0.355. This would suggest that T2 Biosystems's shares are less volatile than average (for this exchange).
T2 Biosystems, Inc. , an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .